Cargando…
Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
INTRODUCTION: Primary debulking surgery (PDS), interval debulking surgery (IDS), and platinum-based chemotherapy are the current standard treatments for advanced ovarian cancer (OC). The time to initiation of adjuvant chemotherapy (TTC) could influence patient outcomes. METHODS: We conducted a multi...
Autores principales: | Farolfi, Alberto, Petracci, Elisabetta, Gurioli, Giorgia, Tedaldi, Gianluca, Casanova, Claudia, Arcangeli, Valentina, Amadori, Andrea, Rosati, Marta, Stefanetti, Marco, Burgio, Salvatore Luca, Cursano, Maria Concetta, Lolli, Cristian, Zampiga, Valentina, Cangini, Ilaria, Schepisi, Giuseppe, De Giorgi, Ugo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468566/ https://www.ncbi.nlm.nih.gov/pubmed/37664032 http://dx.doi.org/10.3389/fonc.2023.1221096 |
Ejemplares similares
-
Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients
por: Gurioli, Giorgia, et al.
Publicado: (2022) -
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2020) -
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018) -
The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment
por: Brighi, Nicole, et al.
Publicado: (2019) -
Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2019)